Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to protect against bacterial diseases. The company utilizes its proprietary XpressCF cell-free protein synthesis platform to engineer complex proteins and antigens for conjugate and protein vaccine candidates. Its primary pipeline consists of a pneumococcal conjugate vaccine (PCV) franchise, including VAX-31, a 31-valent broad-spectrum candidate for adults and infants, and VAX-24, a 24-valent candidate for infants. VAX-31 is designed to provide coverage against invasive pneumococcal disease and pneumonia, with the potential to cover a wider range of serotypes than currently marketed vaccines. The company also maintains early-stage programs targeting Group A Strep and Shigella. Vaxcyte serves the global vaccine market, with a specific focus on the United States for its adult and pediatric indications. The company was founded in 2013 and is investing in expanding its U.S. manufacturing capabilities in North Carolina.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage vaxcyte.com
Sector Healthcare IR page investors.vaxcyte.com
Tags
vaccines, pneumococcal disease, cell-free protein synthesis, conjugate vaccines, bacterial infections, clinical-stage, immunology, pediatric vaccines, adult vaccines, XpressCF, VAX-31, VAX-24, VAX-XL, Prevnar 20, PCV20
Press page —

Metrics

Valuation  
Market cap $ 10.168B
Market cap (USD) $ 10.168B
P/E -8.44
PEG —
P/BV 4.08
P/S —
P/OCF -10.57
P/FCF -10.43
Dividend yield —
Turnover / mcap —
Returns  
ROE -25.6%
ROI -29.2%
ROIC -26.4%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 18
Quality score -69.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 3.003B 3.511B 1.408B 1.006B 324.337M 392.826M 65.698M
Net profit -766.628M -463.927M -402.266M -223.485M -100.077M -89.217M -50.274M
Free cash flow -669.29M -475.054M -312.852M -176.445M -127.948M -47.783M -48.34M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 46.14 81.86 62.8 47.95 23.79 26.57 —
Price performance 12m -0.44 0.3 0.31 1.02 -0.1 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 161,000 0.00 16.8M 17.9M 29.2M 71.1M 117M
Cash and deposits (USD) 36.1M 66.1M 59M 386M 69M 835M 397M 388M 174M
Right-of-use assets (USD) — — — 900,000 28M 21.3M 31M 72.1M 116M
Cash flow detail
Operating cash flow (USD) — -30.5M -47.1M -46.6M -121M -171M -297M -453M -656M
Purchases of property, plant and equipment (USD) — -1.77M -1.2M -1.16M -6.56M -5.85M -16.1M -22.4M -13.7M
Change in payables (cash effect) (USD) — 1.27M 868,000 26.1M -12.5M 2.9M 11.2M 34.6M 19.9M
Interest paid (cash effect) (USD) — -75,000 -40,000 -7,000 -7,000 -2,000 0.00 — —
Share-based compensation (USD) — 749,000 1.19M 5.43M 10.7M 23.7M 48.8M 84.8M 139M
Free cash flow (OCF - PPE - intangibles) (USD) — -32.2M -48.3M -47.8M -128M -176M -313M -475M -669M
Income detail
Research and development expense (USD) — 30.1M 45.6M 73.6M 78.4M 169M 332M 477M 794M
↳ 5y CAGR +61.6% +59.9% +60.9%
Total comprehensive income (USD) — — -50.3M -89.2M -100M -224M -402M -468M -761M
Comprehensive income to owners (USD) — — -50.3M -89.2M -100M -224M -402M -468M -761M
Reported Mar 29, 2021 Mar 29, 2021 Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Feb 27, 2023 Feb 27, 2024 Feb 25, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026

PDF Version

VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages Studied

VAX-31 Adult Indication: Company Expects to Report Results from OPUS-2 and OPUS-3 Phase 3 Trials in First Half of 2027, Supporting Planned Biologics License Application Submission in First Half of 2028

VAX-31 Infant Indication: Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027

Phase 1 Study of VAX-A1, the Company’s Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus, Advancing to Stage 2 in Adults

Pro Forma Cash, Cash Equivalents and Investments of Approximately $3.4 Billion as of September 30, 2026, Including Approximately $1.1 Billion in Net Proceeds from October 2026 Equity and Convertible Senior Notes Offerings

SAN CARLOS, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“The positive topline results from OPUS-1 represent a significant milestone for Vaxcyte and our broad-spectrum pneumococcal conjugate vaccine (PCV) franchise,” said Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte. “VAX-31 met all prespecified primary endpoints in this pivotal Phase 3 trial, which inaugurated a more stringent noninferiority standard, and we believe the results further support its potential best-in-class profile. With OPUS-1 serving as the foundation of our planned Biologics License Application (BLA), we remain on track to announce results from the OPUS-2 and OPUS-3 Phase 3 trials in the first half of next year and, together with a manufacturing consistency study, we expect to submit a BLA in the first half of 2028. For the VAX-31 infant indication, we expect to announce topline data from the primary immunization series and booster dose of the ongoing Phase 2 study, either sequentially or together, by the end of the first half of 2027.”

“Following our positive OPUS-1 results, we completed concurrent equity and convertible senior notes offerings, raising approximately $1.1 billion in net proceeds, to further strengthen our balance sheet and extend our cash runway,” said Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte. “With approximately $3.4 billion in pro forma cash, cash equivalents and investments as of September 30, 2026, we are well positioned to support the potential U.S. commercial launch of VAX-31 for adults and advance our other key initiatives, including the VAX-31 OPUS-2 and OPUS-3 adult Phase 3 studies, the VAX-31 infant Phase 2 study, scale-up of our manufacturing and supply chain, and our earlier stage pipeline including VAX-A1 and VAX-XL.”

Key Third Quarter and Recent Highlights

PCV Franchise Adult Indication:

Reported Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31: In October 2026, the Company announced positive topline results from OPUS-1, which evaluated the safety, tolerability and immunogenicity of VAX-31, its next-generation 31-valent PCV candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. The randomized, double-blind, active-controlled trial evaluated VAX-31 in 4,047 healthy, pneumococcal-naïve1 U.S. adults, including 3,572 aged 50 years and older and 475 aged 18-49. The results will serve as the cornerstone of a planned BLA submission, which will be subject to U.S. Food and Drug Administration (FDA) review.

In the OPUS-1 trial, VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older:

  • All 28 VAX-31 serotypes shared with Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) met the prespecified noninferiority criteria based on opsonophagocytic activity (OPA) geometric mean ratios (GMRs), using a lower bound of the 95% confidence interval (LBCI) >0.667.2

  • For the 11 serotypes shared by VAX-31, PCV20 and PCV21, VAX-31 met all 11 primary noninferiority assessments based on OPA GMRs. For each serotype, the prespecified analysis required noninferiority against at least one comparator, with prespecified multiplicity adjustment.2

  • For the nine serotypes only in VAX-31 and PCV20, all nine met the prespecified OPA GMR noninferiority criterion.3

  • For the eight serotypes only in VAX-31 and PCV21, all eight met the prespecified OPA GMR noninferiority criterion.3

  • The three serotypes unique to VAX-31 along with cross-reactive serotype 20B met the OPA GMR superiority criterion (LBCI >2.0) with prespecified multiplicity adjustment.2

For the prespecified primary immunobridging endpoint, VAX-31 met the noninferiority criterion (LBCI >0.667) for all 324 serotype OPA GMR comparisons in adults aged 18-49 compared to adults aged 50-64.

In the study, VAX-31 was well tolerated and demonstrated a safety profile similar to PCV20 and PCV21 at all ages studied. No serious adverse events were considered to be related to study vaccines, and there were no study discontinuations due to adverse events.

In the prespecified individual comparator analyses, VAX-31 met the noninferiority criterion (LBCI >0.667)3 for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21. Compared to PCV21, serotypes 3 and 12F did not meet the LBCI >0.667 noninferiority criterion, but did meet the historical LBCI >0.5 threshold; compared to PCV20, VAX-31 met the LBCI >0.667 noninferiority criterion.5 Given current U.S. epidemiology, with the serotypes unique to PCV21 accounting for a larger share of adult disease than those unique to PCV20, the Company expects the comparison of VAX-31 to PCV21 to be a particular focus of FDA review.

OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027, Supporting Planned BLA Submission in First Half of 2028: The OPUS-2 and OPUS-3 Phase 3 trials, which are fully enrolled, are designed to generate a broad and robust safety, tolerability and immunogenicity dataset as part of the OPUS Phase 3 program evaluating VAX-31 for the prevention of IPD and pneumococcal pneumonia. In addition, the Company is planning a manufacturing consistency study as the final Phase 3 study to enable the submission of the BLA.

  • The OPUS-2 Phase 3 study, in which 1,390 participants were dosed, is evaluating the safety, tolerability and immunogenicity of VAX-31 when administered either concomitantly with or one month following administration of a licensed seasonal influenza vaccine in healthy, pneumococcal-naïve U.S. adults aged 50 years and older. The results of this descriptive study are intended to inform the design of a potential post-licensure outcomes study that further evaluates VAX-31 in concomitant use with an influenza vaccine and to provide supportive evidence as part of the broader Phase 3 dataset.

  • The OPUS-3 Phase 3 descriptive study, in which 752 participants were dosed, is evaluating the safety, tolerability and immunogenicity of VAX-31 in healthy U.S. adults aged 50 years and older who have previously received pneumococcal vaccination. Among other objectives, the study will evaluate responses to serotypes included in the lower-valency pneumococcal vaccines and the ability of VAX-31 to expand the breadth of serotype-specific immune responses.

Early-Stage Pipeline:

VAX-A1 Phase 1 Study in Adults Advancing to Stage 2: VAX-A1 is an investigational prophylactic vaccine candidate designed to provide broad protection against disease caused by Group A Streptococcus. The VAX-A1 Phase 1 study initiated in June 2026 is advancing to Stage 2 following the completion of an independent Data Safety Monitoring Board (DSMB) review of Stage 1 safety and tolerability data. The Company is completing plans to initiate Stage 2 including an updated study design that incorporates the DSMB’s recommendations for sequential enrollment, beginning with the Low and Mid Dose cohorts. Enrollment of the High Dose cohort will be part of a new Stage 3 and will follow completion of the prespecified safety assessments and further DSMB review and approval. The study design has also been updated to add a third vaccination at the Low and Mid Dose levels, while the High Dose regimen remains two vaccinations. These updates are consistent with the stepwise evaluation of safety, tolerability and dosing regimens in first-in-human vaccine development, which is designed to identify the dose that best balances immune response and tolerability.

The randomized, observer-blind, placebo-controlled, dose-escalation study is designed to enroll approximately 80 healthy adults aged 18 to 40 years in Australia. The primary objective is to assess safety and tolerability, with a secondary objective of evaluating immune responses. Participants will be followed for safety through six months after their last vaccination.

Financing:

Completed Public Offerings Generating $1.15 Billion in Gross Proceeds: In October 2026, the Company completed concurrent underwritten public offerings which generated an aggregate $1.15 billion in gross proceeds, consisting of a $575 million offering of common stock and pre-funded warrants and a $575 million offering of convertible senior notes which bear interest at 1.50% per annum and mature in October 2032. The offerings included the full exercise of the underwriters’ options. Aggregate net proceeds were approximately $1.1 billion after underwriting discounts and commissions and estimated offering expenses.

Executive Leadership Team:

Appointed Chief Medical Officer and Chief Legal Officer: In September 2026, the Company announced the appointments of experienced industry leaders Luis Jodar, Ph.D., as Chief Medical Officer and David McAvoy, J.D., as Chief Legal Officer.

  • Dr. Jodar has more than 30 years of experience in vaccine development and launch across industry, international health organizations and academia. He spent 17 years at Pfizer Inc., most recently as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases.

  • Mr. McAvoy brings more than three decades of legal leadership in the biopharmaceutical industry to Vaxcyte. He joined the Company from Teva Pharmaceutical Industries Ltd., where he served as Executive Vice President and Chief Legal Officer.

Anticipated Program Milestones

Vaxcyte is advancing the clinical development of its pipeline programs with several key milestones anticipated:

VAX-31 Adult Indication

  • Announce safety, tolerability and immunogenicity data from the OPUS-2 and OPUS-3 Phase 3 trials in the first half of 2027.

VAX-31 Infant Indication

  • Announce topline safety, tolerability and immunogenicity data from the VAX-31 infant Phase 2 randomized, dose-finding study from both the primary three-dose immunization series and booster dose either sequentially or together by the end of the first half of 2027.

VAX-A1

  • Announce topline data from the Phase 1 study in adults in the second half of 2027.

Upcoming Investor Conferences

Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences. A live webcast of the fireside chats will be accessible through the Investors & Media section of the Company's website at http://investors.vaxcyte.com for approximately 30 days following each conference.

  • Guggenheim Healthcare Innovation Conference, November 9-11: Fireside chat will take place live on Tuesday, November 10, at 1:00 p.m. ET / 10:00 a.m. PT.

  • UBS Global Biopharma Conference, November 16-17: Presentation will take place live on Tuesday, November 17, at 4:00 p.m. GMT / 11:00 a.m. ET / 8:00 a.m. PT.

  • Jefferies London Healthcare Conference, November 16-19: Fireside chat will take place live on Wednesday, November 18, at 9:00 a.m. GMT / 4:00 a.m. ET / 1:00 a.m. PT.

  • Evercore Healthcare Conference, November 30 to December 2: Fireside chat will take place live on Tuesday, December 1, at 9:35 a.m. ET / 6:35 a.m. PT.

Third Quarter 2026 Financial Results

  • Cash Position: Cash, cash equivalents and investments were $2,264.4 million as of September 30, 2026, compared to $2,442.6 million as of December 31, 2025. The approximately $1.1 billion in net proceeds from the October 2026 offerings are not included in the September 30, 2026 balance.

  • **Research & Development (R&D) Expenses:**R&D expenses were $270.3 million for the three months ended September 30, 2026 as compared to $209.9 million for the same period in 2025. The increase was due primarily to higher development and product manufacturing costs associated with the Company's PCV programs, including manufacturing activities to support the potential future commercial launches and clinical trial expenses primarily related to the VAX-31 OPUS Phase 3 trials, as well as higher personnel expenses related to the growth in the number of R&D employees.

  • **General & Administrative (G&A) Expenses:**G&A expenses were $37.9 million for the three months ended September 30, 2026 as compared to $32.4 million for the same period in 2025. The increase was due primarily to higher personnel expenses related to the growth in the number of G&A employees and professional and consulting services.

  • **Net Loss:**For the three months ended September 30, 2026, net loss was $297.1 million, compared to $212.8 million for the same period in 2025.

About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, has generated positive Phase 2 clinical results in both adults and infants and is designed to cover more serotypes than any PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.

VAX-A1 is a prophylactic vaccine candidate designed to provide broad, strain-independent protection against disease caused by Group A Strep and is currently being evaluated in a Phase 1 clinical study in adults. Group A Strep remains a significant global cause of morbidity and mortality across both adult and pediatric populations and is a leading driver of antibiotic use, underscoring the substantial public health burden.

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte’s carrier-sparing platform and vaccine candidates, including breadth of coverage, the ability to deliver potentially best-in-class vaccines and improve upon the standard-of-care; the design, timing, progress and expected results of Vaxcyte's clinical trials and regulatory plans along with the standards for review and licensure of vaccines and regulators accepting our study as designed; the Company’s planned BLA submission for VAX-31; the future commercialization of Vaxcyte’s PCV programs; Vaxcyte’s cash runway; and other statements that are not historical fact. The words “anticipate,” “believe,” “could,” “expect,” “intend,” “plan,” “may,” “on track,” “potential,” “should,” “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; and sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on November 4, 2026 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date, and readers should not rely upon the information in this press release as current or accurate after its publication date. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

October 9, 2026

PDF Version

SAN CARLOS, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced concurrent underwritten public offerings of 8,584,375 shares of common stock at a public offering price of $64.00 per share, pre-funded warrants to purchase 400,000 shares of common stock at a public offering price of $63.999 per pre-funded warrant and $575 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). These offerings included the exercise in full by the underwriters of their option to purchase up to 1,171,875 additional shares of common stock at the public offering price per share and their option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from these offerings were approximately $1.15 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.

Vaxcyte intends to use the net proceeds from the offerings to fund (i) clinical development of the VAX-31 adult and pediatric programs, including (a) for the ongoing VAX-31 adult Phase 3 program, the trial evaluating concomitant administration with a seasonal influenza vaccine (OPUS-2, enrolled), the trial in adults who have previously received a pneumococcal vaccine (OPUS-3, enrolled) and the planned manufacturing consistency study, and the anticipated topline safety, tolerability and immunogenicity data announcements from such studies, and (b) for the VAX-31 infant Phase 2 dose-finding study (enrolled), the anticipated topline data announcement(s) from the primary three-dose immunization series and booster dose; (ii) manufacturing scale-up, processes and supply to support its clinical studies and the potential commercial launches of its PCV programs, including (a) to establish additional manufacturing capacity to meet potential incremental supply requirements for the global adult and pediatric populations following the potential initial commercial launch of VAX-31 in adults in the United States and (b) to build inventory levels in advance of such potential commercial launch; (iii) medical affairs, commercial and systems-related investments to prepare for and execute the anticipated U.S. launch of VAX-31 in adults; (iv) ongoing research and development of its other early-stage pipeline vaccine candidates; and (v) general corporate purposes, including working capital, operating expenses and capital expenditures, as well as potential expansion of Vaxcyte’s research pipeline.

Jefferies, Leerink Partners, BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC and Guggenheim Securities acted as joint book-running managers for the common stock and pre-funded warrant offering. Mizuho acted as bookrunner and BTIG acted as lead manager for the common stock and pre-funded warrant offering.

Jefferies, Leerink Partners, BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI acted as joint book-running managers for the note offering. Guggenheim Securities and Mizuho acted as bookrunners and Needham & Company acted as lead manager for the note offering.

J. Wood Capital Advisors acted as financial advisor to Vaxcyte in connection with the note offering.

A shelf registration statement relating to the offered securities was filed with the Securities and Exchange Commission (SEC) and was automatically effective upon filing on May 24, 2024. A final prospectus supplement and accompanying prospectus relating to each offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to each offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at [email protected]; or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by email at [email protected] or by phone at (800) 808-7525, ext. 6105.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vaxcyte

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, has generated positive Phase 2 clinical results in both adults and infants and is designed to cover more serotypes than any PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages Vaxcyte’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in Vaxcyte’s PCV franchise.

VAX-A1 is a prophylactic vaccine candidate designed to provide broad, strain-independent protection against disease caused by Group A Strep and is currently being evaluated in a Phase 1 clinical study in adults. Group A Strep remains a significant global cause of morbidity and mortality across both adult and pediatric populations and is a leading driver of antibiotic use, underscoring the substantial public health burden.

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, Vaxcyte’s system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella.

Forward-Looking Statements

This press release contains forward-looking statements regarding Vaxcyte, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the intended use of the net proceeds from the offerings. Words such as “expects,” “intends,” “intended,” “designed,” “aim,” “will” and “may” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements represent Vaxcyte’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are risks described under the caption “Risk Factors” in the prospectus supplements for the offerings, risks relating to Vaxcyte’s business, and the other risks described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. You should not place undue reliance on these forward-looking statements. The forward-looking statements included in this press release speak only as of the date of this press release, and Vaxcyte does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.

On October 9, 2026, Vaxcyte, Inc. (“Vaxcyte”) consummated the sale and issuance of $575,000,000 aggregate principal amount of its 1.50% Convertible Senior Notes due 2032 (the “Notes”) to certain underwriters (the “Debt Offering”). The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of October 9, 2026, between Vaxcyte and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a First Supplemental Indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of October 9, 2026, between Vaxcyte and the Trustee. The Notes are senior, unsecured obligations and will accrue interest at a rate of 1.50% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2027. The Notes will mature on October 15, 2032 unless earlier repurchased, redeemed or converted. Before July 15, 2032, noteholders will have the right to convert their Notes only upon the occurrence of certain events.

Prompts

Vaxcyte, Inc. (ticker PCVX), listed in United States.

Company History

Date Change Detail
Nov 8, 2019 Renamed SutroVax, Inc. → VAXCYTE, INC.

ETFs Holding Vaxcyte, Inc.

ETF Weight in ETF Shares Market value As of
MEDI 3.50% 23,584 $ 1.526M Nov 12, 2026
FMED 1.83% 15,571 $ 945.783K Aug 31, 2026
JXX 1.76% 8,672 $ 468.982K Jul 31, 2026
MKTN short -1.38% -25,399 $ -1.476M Jun 30, 2026
TMED 1.18% 4,655 $ 270.595K Jun 30, 2026
TCAF 0.96% 1,687,475 $ 103.965M Nov 17, 2026
PINK 0.94% 53,169 $ 3.158M Nov 17, 2026
SCDS 0.56% 862 $ 51.203K Nov 17, 2026
FTKI 0.42% 1,749 $ 107.756K Nov 16, 2026
MSSM 0.37% 43,916 $ 2.667M Aug 31, 2026
FSEV 0.26% 304 $ 17.672K Jun 30, 2026
RESM 0.26% 164 $ 9,533.32 Jun 30, 2026
FSEG 0.22% 213 $ 12.382K Jun 30, 2026
FFSM 0.21% 58,584 $ 3.168M Jul 31, 2026
TMSL 0.20% 95,215 $ 5.535M Jun 30, 2026
FFLG 0.17% 18,030 $ 975.062K Jul 31, 2026
ESSC 0.16% 1,044 $ 56.46K Jul 31, 2026
FFF 0.15% 167 $ 9,502.30 Sep 30, 2026
FESM 0.13% 131,640 $ 7.652M Jun 30, 2026
VFMO 0.13% 40,552 $ 2.463M Aug 31, 2026
DFAS 0.11% 547,296 $ 35.405M Nov 12, 2026
AVMC 0.09% 8,282 $ 510.254K Nov 16, 2026
AVIE 0.07% 191 $ 11.768K Nov 16, 2026
DXUV 0.03% 29,958 $ 1.938M Nov 12, 2026
FBCG 0.03% 32,976 $ 1.783M Jul 31, 2026
DFAC 0.02% 288,368 $ 18.655M Nov 12, 2026
AVLC 0.02% 4,584 $ 282.42K Nov 16, 2026
DFAU 0.02% 35,372 $ 2.288M Nov 12, 2026
DFUS 0.01% 45,083 $ 2.916M Nov 12, 2026
AVUS 0.01% 22,093 $ 1.361M Nov 16, 2026
DCOR 0.00% 25,551 $ 1.653M Nov 12, 2026
AVSU 0.00% 28 $ 1,725.08 Nov 16, 2026
NTRL short 0.00% -667 $ 0.00 Nov 16, 2026